JP2020507596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507596A5 JP2020507596A5 JP2019543851A JP2019543851A JP2020507596A5 JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5 JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- subject
- pharmaceutical composition
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216425A JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Division JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507596A JP2020507596A (ja) | 2020-03-12 |
| JP2020507596A5 true JP2020507596A5 (enExample) | 2021-04-01 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (enExample) |
| EP (1) | EP3582805A4 (enExample) |
| JP (2) | JP2020507596A (enExample) |
| KR (3) | KR20230145547A (enExample) |
| CN (2) | CN110290803A (enExample) |
| AU (2) | AU2018221822A1 (enExample) |
| CA (1) | CA3052652A1 (enExample) |
| EA (1) | EA201991870A1 (enExample) |
| IL (3) | IL320916A (enExample) |
| MA (1) | MA47509A (enExample) |
| SG (1) | SG11201907211TA (enExample) |
| WO (1) | WO2018152415A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2023526400A (ja) * | 2020-05-21 | 2023-06-21 | アストラゼネカ・アクチエボラーグ | 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量 |
| WO2026003724A1 (en) * | 2024-06-25 | 2026-01-02 | Astrazeneca Ab | Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| KR20170132171A (ko) * | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 ｐｄ１ ／ ｐｄｌ１ 저해제 |
| EP3303632B2 (en) * | 2015-05-29 | 2023-05-10 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
-
2018
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en not_active Abandoned
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| JP2018522850A5 (enExample) | ||
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| JP2022531408A5 (enExample) | ||
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2013520442A5 (enExample) | ||
| JP2024038034A5 (enExample) | ||
| CN108498532A (zh) | 骨髓抑制的治疗 | |
| Hyung et al. | Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| Lignon et al. | Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| Rose et al. | A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study | |
| Fujimoto et al. | A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol | |
| Sun et al. | Programmed cell death 1 (PD‐1)/PD‐ligand 1 (PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| Nardi et al. | FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study | |
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| JP2022501332A5 (enExample) | ||
| Uranga et al. | Gastrointestinal side effects of anticancer therapy | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients | |
| Schieber et al. | Tarlatamab rechallenge after grade 3 cytokine release syndrome leading to tumor regression in two weeks and reopening of a collapsed lung: a case report | |
| US9770462B2 (en) | Method of treating ovarian, tubal and peritoneal cancer |